Related news from
Mon, 26 Jan 2026 18:27:34 +0000	IBD Stock Of The Day: Why Cardinal Health's Momentum Is 'Special' — And Not Over Yet Cardinal Health is Monday's IBD Stock Of The Day. Shares are rebounding off their 21-day line, helped by continued biopharma momentum.
Sun, 25 Jan 2026 09:46:28 +0000	Here Are the Top Four Blue-Chip Stocks To Buy in 2026, According to WarrenAI Investing.com -- Blue chip stocks in the healthcare sector are showing exceptional growth potential according to recent rankings from WarrenAI. The analysis highlights four standout companies that combine strong fundamentals with significant upside potential, making them attractive options in today’s market.
Sat, 24 Jan 2026 14:06:34 +0000	Assessing Cencora (COR) Valuation After Strong Returns And Conflicting Fair Value Signals What Cencora’s Recent Share Moves Signal for Investors Cencora (COR) has caught investor attention after a steady run, with the stock closing at $353.48 and showing positive total returns over the past year and over the past 3 months. The company reports annual revenue of about $321.3b and net income of $1.6b, alongside annual revenue growth of 6.2% and net income growth of 17.4%. These figures give investors concrete fundamentals to weigh against recent share performance. See our latest...
Thu, 22 Jan 2026 14:00:00 +0000	Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products ATLANTA, January 22, 2026--Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing rare disease therapies with an integrated solution to support the commercialization of their products.
Thu, 22 Jan 2026 12:30:00 +0000	Cencora Elects Ellen Cooper to Its Board of Directors CONSHOHOCKEN, Pa., January 22, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026.
Mon, 12 Jan 2026 17:47:53 +0000	Jim Cramer Says “Cardinal Is Really the Monster” Among Drug Distributors Cardinal Health, Inc. (NYSE:CAH) is one of the stocks from different market sectors that Jim Cramer commented on. Cramer highlighted the company’s noteworthy performance, as he commented: “The drug distributors continue to relentlessly climb higher. There’s nothing, you know, people hate the pharma middleman. Even the president doesn’t talk, like… them. But I got to […]
Mon, 12 Jan 2026 12:51:00 +0000	3 Medical Supplies Stocks That Beat the Market Despite Macro Headwinds Cardinal Health, McKesson, and Cencora are showing how scale, specialty focus, and execution can drive market-beating returns despite macro pressure.
Fri, 09 Jan 2026 18:13:53 +0000	Cencora (COR) Valuation Check As Share Price Momentum Cools After Recent Gains Cencora (COR) shares have been relatively muted recently, with a 1-day decline of about 1% and a roughly flat return over the past month, even as the stock shows a strong total return over the past year. See our latest analysis for Cencora. The recent softness in Cencora’s share price, with the stock now at $335.74 and a small 90 day share price gain, contrasts with its much stronger 1 year and multi year total shareholder returns. This suggests momentum has cooled even as long term holders...
Fri, 09 Jan 2026 14:06:54 +0000	What to Expect From Cencora's Next Quarterly Earnings Report Cencora is set to report its first-quarter earnings next month, and analysts are anticipating a single-digit increase in its bottom line.
Thu, 08 Jan 2026 12:57:00 +0000	Here's Why You Should Retain Cencora Stock in Your Portfolio Now Cencora's strength in U.S. Healthcare Solutions, along with rising specialty drug demand and biosimilar adoption, supports growth, though competitive pressures and international weakness remain headwinds.
Wed, 07 Jan 2026 04:36:04 +0000	3 Healthcare Stocks with Exciting Potential Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 19.9% gain over the past six months, beating the S&P 500 by 9.1 percentage points.
Tue, 06 Jan 2026 21:30:00 +0000	Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release CONSHOHOCKEN, Pa., January 06, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026.
Mon, 05 Jan 2026 18:44:00 +0000	McKesson Builds Earnings Momentum on Specialty and Automation McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.
Mon, 05 Jan 2026 17:43:16 +0000	Drug Distributors Poised for Growth Amid Emerging Risks, BofA Says Cencora (COR), McKesson (MCK), and Cardinal Health (CAH) performed strongly in 2025, and the drug di
Fri, 02 Jan 2026 04:39:29 +0000	2 Large-Cap Stocks Worth Your Attention and 1 We Question Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Tue, 30 Dec 2025 12:33:00 +0000	Reasons to Add Cooper Companies Stock to Your Portfolio Now COO's revenues are showing strong growth as MyDay and MiSight drive momentum, while restructuring savings and buybacks bolster long-term upside despite near-term risks.
Mon, 29 Dec 2025 15:17:00 +0000	Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.
Mon, 29 Dec 2025 13:52:00 +0000	Here's Why You Should Retain Glaukos Stock in Your Portfolio Now GKOS appears well-positioned for long-term growth as iDose TR adoption accelerates and Epioxa secures FDA approval, although reimbursement and execution risks remain.
Fri, 26 Dec 2025 12:18:00 +0000	Reasons to Retain Baxter International Stock in Your Portfolio Now BAX is reshaping its portfolio following the divestiture of Kidney Care, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.
Thu, 25 Dec 2025 03:36:29 +0000	Q3 Rundown: Cencora (NYSE:COR) Vs Other Health Insurance Providers Stocks As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at health insurance providers stocks, starting with Cencora (NYSE:COR).

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!